NCT06075576已完成不适用
Characterization of the Central and Peripheral Wavefront Aberration Profile in Pediatric Myopic Subjects
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 23
- 试验地点
- 1
- 主要终点
- Peripheral aberration profile of pediatric myopia population under cycloplegic conditions for distance
研究概览
简要总结
This is a 3-visit, single site, observational clinical study to evaluate the characterization of the central and peripheral wavefront aberration profiles in pediatric myopic subjects.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 6 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Potential subjects must satisfy all of the following criteria to be enrolled in the study:
- •The subject must:
- •Read or (be read to) and sign the CHILDREN'S ASSENT (information and assessment form) and receive a fully executed copy of the form.
- •Have parents or legal guardians who must read, understand, and sign the STATEMENT OF INFORMED CONSENT FORM and receive a fully executed copy of the form.
- •Appear able and willing to adhere to the instructions set forth in this clinical protocol.
- •Be at least 6 years of age and not greater than 17 years of age at the time of consent.
- •The subjects are required to be within -1.00 to -6.00 D (inclusive) for the spherical component of vertex- corrected refraction.
- •The magnitude of cylindrical component of the subject's vertex distance corrected distance refraction must be between 0.00 and 2.25 D in each eye.
- •The subject must have distance best corrected visual acuity of 20/25 or better in each eye.
排除标准
- •Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- •The subject must not:
- •Be currently pregnant or lactating.
- •Be diabetic.
- •Be currently using any ocular medications or have any ocular infection of any type.
- •By self-report, have any ocular or systemic disease, allergies, infection, or use of medication that may otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g., rheumatoid arthritis, Sjögren's syndrome), or history of serious mental illness or seizures. See section 9.1 for additional details regarding excluded systemic medications.
- •Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g., SynergEyes, SoftPerm) within the past 6 months.
- •History of pharmacologic treatment for myopia within the past 2 years.
- •Have participated in any study using pharmacologic agents within 30 days prior to study enrollment.
- •Use of any ocular medication, except for rewetting drops.
- •Have a history of pathological dry eye.
- •Be an employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
- •Have any known hypersensitivity or allergic reaction to rewetting drop solutions, topical anesthetic (Proparacaine), topical cycloplegic drops (Tropicamide) or sodium fluorescein.
- •Have clinically significant (grade 3 or higher on the FDA grading scale) slit lamp findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection) or other corneal or ocular disease or abnormalities may otherwise compromise study endpoints (including entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis).
- •Have a history of strabismus or amblyopia.
- •Have fluctuations in vision due to clinically significant dry eye or other ocular conditions.
- •Have had or have planned (within the study period) any ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, iridotomy, retinal laser photocoagulation, etc.).
- •Intraocular pressure >21 mm of Hg OD or OS.
- •Ocular anterior chamber angle assessed by Van Herick's measurement of grade 2 or less OD or OS.
- •Have latent, manifest nystagmus or any fixation related abnormality (at the discretion of the investigator).
- •Have any corneal scar and/or distortion within the central 6 mm.
结局指标
主要结局
Peripheral aberration profile of pediatric myopia population under cycloplegic conditions for distance
时间窗: up to day 26 from Visit 1
Assessment of peripheral aberration profile of pediatric myopia population under cycloplegic conditions for distance (target at 4m) viewing conditions.
Central aberration profile of pediatric myopia population under cycloplegic conditions for distance
时间窗: up to day 26 from Visit 1
Assessment of central aberration profile of pediatric myopia population under cycloplegic conditions for distance (target at 4m) viewing conditions.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Clinical Study Evaluating Outcomes of Reverse Shoulder Arthroplasty With SMR StemlessRotator Cuff Tear ArthropathyOsteo Arthritis ShouldersNCT04529798Arthro Medics AG60
终止
4 期
The Functional and Emotional Benefits of Replenix Power of Three With ResveratrolAcne VulgarisNCT03563365Yardley Dermatology Associates43
Unknown
不适用
Endosonographic Shear Wave Elastography for Liver StiffnessLiver CirrhosisNCT04533932Midwest Biomedical Research Foundation40
已完成
不适用
ECAP-controlled, Closed-loop Stimulation to Treat Chronic Trunk and/or Limb Pain (ECAP)Chronic PainBack PainPainNCT04319887Saluda Medical Pty Ltd300
已完成
3 期
A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.Coronary Artery DiseaseNCT01347710Lantheus Medical Imaging795